Farnum Rhonda's Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed Feb 22, 2024
- Accession no.
- 0001415889-24-004958
- Filed
- Feb 22, 2024
- Trade date
- Feb 20-22, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $10.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farnum RhondaCIK 0001898490 | Officer (SVP, COMM & MEDICAL AFFAIRS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | Ordinary Shares | FTax withholdingDisposed | −18,219 | $8.92 | −$162,513.48 | 312,987 | Direct | |
| Feb 22, 2024 | Ordinary Shares | SSaleDisposed | −1,254 | $8.71 | −$10,922.34 | 311,733 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.